Wockhardt has achieved a landmark success with the US FDA approval of Zaynich (cefepime and zidebactam), a novel antibiotic for complicated urinary tract infections, marking the first fully developed and commercialized new chemical entity from an Indian pharmaceutical company to gain this approval. This significant development, supported by positive Phase 3 ENHANCE-1 trial data demonstrating Zaynich's superior efficacy compared to meropenem, offers a crucial new treatment option in the global fight against antimicrobial resistance, a growing public health threat responsible for millions of deaths annually. The approval not only validates Wockhardt's extensive efforts in anti-infective drug discovery but also positions India as an innovator in the pharmaceutical landscape, with Zaynich's dual-action mechanism designed to overcome common bacterial resistance pathways and potentially address the escalating crisis of drug-resistant infections worldwide.

Wockhardt has achieved a landmark success with the US FDA approval of Zaynich (cefepime and zidebactam), a novel antibiotic for complicated urinary tract infections, marking the first fully developed and commercialized new chemical entity from an Indian pharmaceutical company to gain this approval. This significant development, supported by positive Phase 3 ENHANCE-1 trial data demonstrating Zaynich's superior efficacy compared to meropenem, offers a crucial new treatment option in the global fight against antimicrobial resistance, a growing public health threat responsible for millions of deaths annually. The approval not only validates Wockhardt's extensive efforts in anti-infective drug discovery but also positions India as an innovator in the pharmaceutical landscape, with Zaynich's dual-action mechanism designed to overcome common bacterial resistance pathways and potentially address the escalating crisis of drug-resistant infections worldwide.

Wockhardt has achieved a landmark success with the US FDA approval of Zaynich (cefepime and zidebactam), a novel antibiotic for complicated urinary tract infections, marking the first fully developed and commercialized new chemical entity from an Indian pharmaceutical company to gain this approval. This significant development, supported by positive Phase 3 ENHANCE-1 trial data demonstrating Zaynich's superior efficacy compared to meropenem, offers a crucial new treatment option in the global fight against antimicrobial resistance, a growing public health threat responsible for millions of deaths annually. The approval not only validates Wockhardt's extensive efforts in anti-infective drug discovery but also positions India as an innovator in the pharmaceutical landscape, with Zaynich's dual-action mechanism designed to overcome common bacterial resistance pathways and potentially address the escalating crisis of drug-resistant infections worldwide.

In a landmark achievement for India's pharmaceutical industry, Wockhardt has received approval from the United States Food and Drug Administration (US FDA) for Zaynich (cefepime and zidebactam), a novel antibiotic designed to treat adults suffering from complicated urinary tract infections (cUTI), including kidney infections. The approval marks a significant breakthrough not only for the Mumbai-headquartered pharmaceutical company but also for India's drug innovation ecosystem, as Zaynich becomes the first fully developed and commercialised new chemical entity (NCE) from an Indian pharmaceutical company to secure approval from the US FDA. 

The approval comes shortly after India's drug regulator granted marketing authorisation for the therapy and follows encouraging results from the global Phase 3 ENHANCE-1 clinical trial. The study evaluated Zaynich against meropenem, one of the most widely used antibiotics for severe bacterial infections, and found the new therapy to be highly effective in treating difficult urinary tract and kidney infections. 

According to estimates published by the World Health Organisation (WHO), antimicrobial resistance was associated with nearly 5 million deaths globally in 2019, including 1.27 million deaths directly attributable to bacterial resistance. Considering that antimicrobial resistance (AMR) is among the world's fastest-growing public health threats, the approval of Zaynich could open an important new treatment option for patients suffering from severe drug-resistant infections.  

The story behind Zaynich's historic approval

Wockhardt said the approval represents a defining moment in the company's decades-long effort to develop innovative anti-infective medicines and establishes India as a contributor to global drug discovery rather than merely a manufacturer of generic medicines. 

The company stated that Zaynich is the first new chemical entity fully developed and commercialised by an Indian pharmaceutical company to receive approval from the US FDA. Unlike generic medicines, which are copies of existing drugs, a new chemical entity represents a completely new medicine with a unique molecular structure and therapeutic profile. 

"This approval is a significant realisation of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats - antimicrobial resistance," said Dr Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group. 

"Furthermore, ZAYNICH is the first New Chemical Entity fully developed and commercialised by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry," he added. 

The approval was supported by data from the Phase 3 ENHANCE-1 trial, a large international study involving 530 patients across 64 hospitals and research centres located in the United States, Europe, Latin America, China and India. The trial enrolled hospitalised adults diagnosed with complicated urinary tract infections or acute pyelonephritis and compared the effectiveness of Zaynich against meropenem, a standard treatment used worldwide for serious bacterial infections. 

According to the company, the study demonstrated a strong clinical advantage for Zaynich. Researchers found that 89 per cent of patients treated with Zaynich achieved both clinical cure and microbiological eradication of the infection. In comparison, 68.4 per cent of patients receiving meropenem achieved the same outcome. This translated into a treatment advantage of 20.6 percentage points in favour of the new therapy. 

The antibiotic has been specifically designed to address some of the most difficult-to-treat bacterial infections. Wockhardt said Zaynich works through a dual-action mechanism that enables it to overcome several common bacterial resistance pathways that often render existing antibiotics ineffective.  

"The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of ZAYNICH is a monumental step forward in validating a new option for these underserved populations," said Dennis Deruelle, Chief Medical Officer at Wockhardt. 

The approval arrives against the backdrop of rising antimicrobial resistance globally. Wockhardt cited estimates indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States alone, contributing to more than 35,000 deaths every year. Similar concerns have been reported across many parts of the world, where resistant pathogens continue to increase healthcare costs, prolong hospital stays and raise mortality risks. 

Keith Kaye, Professor of Medicine and Division Chief for Infectious Diseases at Rutgers Robert Wood Johnson Medical School, said the availability of a new antibiotic is particularly important given the growing burden of multidrug-resistant infections. 

"Multidrug-resistant bacterial infections are a substantial burden for patients and the healthcare system, as patients with these infections typically require longer, more intensive care, and are at increased risk of life-threatening complications," he said. 

"There is an ongoing need for new antibiotics to combat these drug-resistant pathogens, and we are pleased that this approval means patients will soon have an exciting, unique option that is urgently needed in the US and worldwide." 

The development journey of Zaynich also benefited from several regulatory incentives provided by the US FDA to encourage antibiotic innovation. The therapy previously received both Priority Review and Fast Track designations, programmes intended to accelerate the development and review of medicines addressing serious conditions and unmet medical needs. 

In addition, Zaynich was granted Qualified Infectious Disease Product (QIDP) status, a special designation created under US legislation to encourage the development of urgently needed antibacterial and antifungal drugs. QIDP designation provides certain regulatory benefits, including priority review and extended market exclusivity. 

Even before receiving full approval, the therapy had been made available through expanded access programmes in multiple countries, allowing patients with limited treatment options to access the medicine under special circumstances. 

The approval also strengthens Wockhardt's broader antibiotics portfolio. The company currently has six antibiotic programmes at various stages of development and commercialisation. According to Wockhardt, all six programmes have received QIDP designation from the US FDA, underscoring the company's focus on addressing antimicrobial resistance through innovative therapies. 

Beyond the United States and India, Wockhardt is seeking to expand the drug's availability to additional markets. The company has already submitted a marketing authorisation application in Europe, where regulatory authorities are currently reviewing the therapy. 

‘A noteworthy scientific achievement from India’ 

Dr (Col) Rajeev Sood, Chairman - Urology, Robotics and Renal Transplant at Manipal Hospitals Gurugram, said Zaynich should be viewed as more than just another antibiotic and as an important addition to the shrinking arsenal against resistant urinary pathogens. 

“As a urologist, I would view Zaynich less as ‘another antibiotic’ and more as an important addition to the shrinking arsenal against resistant urinary pathogens,” he said. 

He noted that resistant urological infections are becoming increasingly difficult to treat, making the development of a novel agent from India noteworthy. 

“The scientific achievement is noteworthy because resistant urological infections are becoming increasingly difficult to treat, and the development of a truly novel agent from India is an encouraging step for both patient care and pharmaceutical innovation,” he added. 

This story is done in collaboration with First Check, which is the health journalism vertical of DataLEADS